# Positrigo

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/positrigo

- Industry: Medical Devices & Equipment
- Headquarters: Zurich, Switzerland
- Website: www.positrigo.com
- Total disclosed funding: $9.8M
- Latest round: Series B (Oct 28, 2022)
- Investors on record: 8

## About

Based in Switzerland, Positrigo AG develops innovative medical imaging technologies, particularly ultra-compact Positron Emission Tomography (PET) systems. Its flagship product, NeuroLF, enhances the diagnosis of neurological disorders.Founded in 2018, Positrigo AG operates from Zurich, Switzerland, focusing on the development of advanced Positron Emission Tomography systems. The company has successfully engaged in 5 funding rounds, raising a total of CHF 7 million, with the latest funding round occurring on June 10, 2025, led by HealthCap. CEO Jannis Fischer is among the founders, contributing to the firm’s vision and strategic direction.Positrigo AG specializes in the development and commercialization of ultra-compact Positron Emission Tomography (PET) systems, with its flagship product being the NeuroLF device. This innovative imaging technology provides functional brain imaging, primarily focusing on the diagnosis of dementia, including Alzheimer’s disease, along with various other neurological disorders such as epilepsy and neuro-oncology. The NeuroLF system is designed to make precision medicine and functional imaging accessible to healthcare providers and patients worldwide, significantly reducing the cost compared to traditional PET devices. Key customer segments include hospitals, research institutions, and clinics that require advanced imaging solutions to enhance patient care. As of now, Positrigo’s products are marketed in the United States and throughout Europe, expanding access to advanced neuroimaging technologies in these regions.Positrigo's revenue model is centered around the direct sale of its NeuroLF PET systems to healthcare providers and research institutions. Additionally, the company engages in strategic partnerships to enhance its distribution capabilities, which includes appointing exclusive distributors in key markets, such as Qualimedis in France. The pricing structure for the NeuroLF system and associated services is tailored to institutional clients, enabling them to incorporate advanced imaging technology into their diagnostic offerings. Revenue is generated primarily through the initial sale of the NeuroLF devices, as well as additional services such as maintenance and technical support, creating a comprehensive customer relationship. This model reflects a focus on B2B transactions, ensuring that healthcare facilities can implement advanced imaging solutions to meet the increasing demand for precision diagnostics.In June 2025, Positrigo AG raised CHF 7 million in venture funding led by HealthCap, with participation from Navivo Capital and other investors. The company will use this funding to boost production and accelerate the commercialization of its NeuroLF brain Positron Emission Tomography (PET) device. Looking ahead, Positrigo plans to expand its market presence by targeting additional regions for product distribution, thus enhancing accessibility to its innovative imaging technologies.

## Funding rounds

- Series B, Oct 28, 2022, $5.5M — Zürcher Kantonalbank, European Innovation Council, ETH Foundation, Fairway Asset Management, 4FO Ventures
- Series A, Jul 10, 2020, $4.2M — Zurich Cantonal Bank, ETH Foundation, 4FO Ventures, Great Filter Ventures
- Seed, Dec 5, 2018, $0.1M — Venture Kick

## Investors

- Venture Kick (https://capitalatlas.ai/funds/venture-kick) — Seed
- Zurich Cantonal Bank — Series A
- ETH Foundation — Series A, Series B
- 4FO Ventures (https://capitalatlas.ai/funds/4fo-ventures) — Series A, Series B
- Great Filter Ventures — Series A
- Zürcher Kantonalbank — Series B
- European Innovation Council (https://capitalatlas.ai/funds/european-innovation-council) — Series B
- Fairway Asset Management (https://capitalatlas.ai/funds/fairway-asset-management) — Series B